常压高氧降低大鼠及急性缺血性卒中患者血中Occludin片段
该研究在大鼠大脑中动脉闭塞模型和接受静脉tPA溶栓的急性缺血性卒中患者中,探讨血紧密连接蛋白作为血脑屏障损伤生物标志物的可行性。结果显示脑缺血/再灌注导致微血管occludin和claudin-5降解、血脑屏障通透性增加,血occludin升高且与微血管丢失相关;常压高氧(100% O2)可减少血occludin并改善神经功能。
要点
- 血occludin可反映缺血/再灌注期间血脑屏障损伤程度。
- 常压高氧降低大鼠和患者血occludin水平并改善神经功能。
- 接受静脉tPA溶栓的AIS患者入院时血occludin已升高并持续72小时。
核心结论
- 血occludin可能是评估缺血/再灌注期间血脑屏障损伤的临床可行生物标志物。
- 常压高氧治疗有潜力降低血occludin、保护血脑屏障并改善接受静脉tPA溶栓的AIS患者结局。
研究设计与样本
- 大鼠大脑中动脉闭塞模型暴露于常压高氧(100% O2)或常氧(21% O2),测定血脑屏障通透性及血和脑微血管中occludin与claudin-5。
- 急性缺血性卒中患者随机接受氧疗或室内空气4小时,在卒中后不同时间点测定血occludin和claudin-5。
- 临床试验注册号NCT02974283。
主要发现
- 大鼠脑缺血/再灌注导致微血管occludin和claudin-5降解,血脑屏障通透性增加。
- 大鼠血occludin在缺血4小时升高并在再灌注期间持续升高,与缺血脑微血管occludin丢失相关良好。
- 常压高氧防止大鼠微血管occludin降解并降低血occludin水平,改善神经功能。
- 接受静脉tPA溶栓的AIS患者入院时(症状出现4.5小时内)血occludin已升高并持续高水平72小时。
- 常压高氧显著降低AIS患者血occludin水平并改善神经功能。
临床怎么用
- 血occludin或可用于评估AIS患者血脑屏障损伤程度,辅助tPA使用决策。
- 常压高氧可能作为接受静脉tPA溶栓AIS患者的辅助治疗以保护血脑屏障。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Damage of the blood-brain barrier (BBB) increases the incidence of neurovascular complications, especially for cerebral hemorrhage after tPA (tissue-type plasminogen activator) therapy. Currently, there is no effective method to evaluate the extent of BBB damage to guide tPA use. Herein, we investigated whether blood levels of tight junction proteins could serve as biomarker of BBB damages in acute ischemic stroke (AIS) in both rats and patients. We examined whether this biomarker could reflect the extent of BBB permeability during cerebral ischemia/reperfusion and the effects of normobaric hyperoxia (NBO) on BBB damage. METHODS: Rats were exposed to NBO (100% O2) or normoxia (21% O2) during middle cerebral artery occlusion. BBB permeability was determined. Occludin and claudin-5 in blood and cerebromicrovessels were measured. Patients with AIS were assigned to oxygen therapy or room air for 4 hours, and blood occludin and claudin-5 were measured at different time points after stroke. RESULTS: Cerebral ischemia/reperfusion resulted in the degradation of occludin and claudin-5 in microvessels, leading to increased BBB permeability in rats. In blood samples, occludin increased with 4-hour ischemia and remained elevated during reperfusion, correlating well with its loss from ischemic cerebral microvessels. NBO treatment both prevented occludin degradation in microvessels and reduced occludin levels in blood, leading to improved neurological functions in rats. In patients with AIS receiving intravenous tPA thrombolysis, the blood occludin was already elevated when patients arrived at hospital (within 4.5 hours since symptoms appeared) and remained at a high level for 72 hours. NBO significantly lowered the level of blood occludin and improved neurological functions in patients with AIS. CONCLUSIONS: Blood occludin may be a clinically viable biomarker for evaluating BBB damage during ischemia/reperfusion. NBO therapy has the potential to reduce blood occludin, protect BBB, and improve outcome in AIS patients with intravenous tPA thrombolysis. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02974283.
引用
- Shi S, Qi Z, Ma Q, et al. Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke. Stroke. 2017. PMID: 28931617. doi:10.1161/STROKEAHA.117.017713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。